Technical Analysis for IKNA - Ikena Oncology, Inc.

Grade Last Price % Change Price Change
F 11.18 -2.70% -0.31
IKNA closed down 2.7 percent on Tuesday, July 27, 2021, on 22 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong N/A Down Down
Historical IKNA trend table...

Date Alert Name Type % Chg
Stochastic Buy Signal Bullish 0.00%
Calm After Storm Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Slingshot Bearish Bearish Swing Setup -2.70%
Calm After Storm Range Contraction -2.70%
New 52 Week Low Weakness -2.70%
Older End-of-Day Signals for IKNA ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Possible Inside Day about 9 hours ago
Possible NR7 about 9 hours ago
Up 1% about 12 hours ago
60 Minute Opening Range Breakout about 12 hours ago
Down 3% about 13 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Ikena Oncology, Inc., a targeted oncology company, focuses on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, a selective AHR antagonist; IK-412, a recombinant human kynurenine-degrading enzyme; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Biology Oncology Colorectal Cancer Cancer Therapies Signal Transduction Transcription Factors Novel Cancer

Is IKNA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 37.61
52 Week Low 10.47
Average Volume 154,326
200-Day Moving Average 0.00
50-Day Moving Average 14.76
20-Day Moving Average 12.75
10-Day Moving Average 11.77
Average True Range 1.56
ADX 26.94
+DI 24.94
-DI 16.93
Chandelier Exit (Long, 3 ATRs) 12.91
Chandelier Exit (Short, 3 ATRs) 15.16
Upper Bollinger Bands 15.22
Lower Bollinger Band 10.28
Percent B (%b) 0.18
BandWidth 38.80
MACD Line -1.02
MACD Signal Line -0.98
MACD Histogram -0.0431
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.02
Resistance 3 (R3) 12.07 11.83 11.88
Resistance 2 (R2) 11.83 11.62 11.81 11.84
Resistance 1 (R1) 11.51 11.48 11.39 11.46 11.79
Pivot Point 11.27 11.27 11.21 11.25 11.27
Support 1 (S1) 10.94 11.05 10.82 10.90 10.57
Support 2 (S2) 10.70 10.92 10.68 10.52
Support 3 (S3) 10.38 10.70 10.48
Support 4 (S4) 10.34